基于网络药理学与分子对接探索人参-五味子配伍治疗特发性肺间质纤维化的分子机制

doi:10.3976/j.issn.1002-4026.2022.01.005

Abstract

Abstract:

Based on the network pharmacology and molecular docking study approach, investigation of the potential molecular mechanism of Ginseng Radix Et Rhizoma-Schisandrae Chinensis Fructus couple medicine in the treatment of idiopathic pulmonary fibrosis (IPF) was conducted. The active ingredients and therapeutic targets of Ginseng Radix Et Rhizoma-Schisandrae Chinensis Fructus couple medicine were selected on a TCM systematic pharmacological analysis platform. The disease targets corresponding to IPF were obtained from the Gene Expression Omnibus, GeneCards and CTD databases. The protein-protein interaction(PPI) network was constructed and analyzed using the STRING online database. Gene ontology(GO) analysis and Kyoto encyclopedia of genes and genomes(KEGG) pathway enrichment analyses of the hub genes were conducted using R language. Overall, 23 active ingredients of Ginseng Radix Et Rhizoma-Schisandrae Chinensis Fructus couple medicine were screened; these active ingredients acted on 48 IPF target genes. Twenty hub genes such as AKT1, PTGS2, and IL1B were screened from the PPI network of target genes, and the docking energy of hub genes and active ingredient molecules of the drug pair were stable and firmly bound. The hub genes were enriched in 67 GO processes, including nuclear receptor activity and steroid receptor activity, and 90 KEGG signaling pathways, such as IL17 signaling pathway and tumor necrosis factor signaling pathway. The combination of Ginseng Radix Et Rhizoma and Schisandrae Chinensis Fructus reinforces Qi and nourishes Yin, which may exert its effects on the treatment of IPF through multiple pathways and mechanisms such as regulation of body immunity, antifibrosis, antioxidative stress, and inhibition of inflammation.

Key words: Ginseng Radix Et Rhizoma, Schisandrae Chinensis Fructus, idiopathic pulmonary fibrosis, network pharmacology, molecular docking

CLC Number:

R285

GU Yi-dan,REN Yun-yan,ZHANG Zhu-feng,GAO Ping. Molecular mechanism of Ginseng Radix Et Rhizoma-Schisandrae Chinensis Fructus couple medicine in the treatment of idiopathic pulmonary fibrosis based on network pharmacology and molecular docking[J].Shandong Science, 2022, 35(1): 28-36.

Figures/Tables 7

Fig.1

Table 1

Fig. 2

Fig. 3

Fig.4

Table 2

Table 3

References 31

[1]	雷凯春, 岳红梅, 周婷婷. 特发性肺纤维化治疗新进展[J]. 中国呼吸与危重监护杂志, 2019, 18(2):199-203. DOI: 10.7507/1671-6205.201706031. doi: 10.7507/1671-6205.201706031
[2]	RAGHU G, COLLARD H R, EGAN JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management[J]. American Journal of Respiratory and Critical Care Medicine, 2011, 183(6):788-824. DOI: 10.1164/rccm.2009-040GL. doi: 10.1164/rccm.2009-040GL
[3]	FERNANDEZ I E, EICKELBERG O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonaryfibrosis[J]. Lancet, 2012, 380(9842):680-688. DOI: 10.1016/S0140-6736(12)61144-1. doi: 10.1016/S0140-6736(12)61144-1
[4]	雷凯春, 岳红梅, 周婷婷. 吡非尼酮治疗特发性肺纤维化的临床疗效及不良反应[J]. 中国新药与临床杂志, 2018, 37(3):160-163. DOI: 10.14109/j.cnki.xyylc.2018.03.009. doi: 10.14109/j.cnki.xyylc.2018.03.009
[5]	刘勇. 川芎嗪联合雾化吸入布地奈德治疗特发性肺纤维化疗效观察[J]. 现代中西医结合杂志, 2015, 24(23):2536-2538.
[6]	张馨心, 吕晓东, 庞立健, 等. 益气养阴法治疗特发性肺间质纤维化疗效Meta分析[J]. 辽宁中医药大学学报, 2020, 22(2):96-100. DOI: 10.13194/j.issn.1673-842x.2020.02.026. doi: 10.13194/j.issn.1673-842x.2020.02.026
[7]	陈海芳, 戚进, 余伯阳. 生脉散中人参、麦冬和五味子提取物体外抗氧化作用[J]. 中国实验方剂学杂志, 2016, 22(19):37-42. DOI: 10.13422/j.cnki.syfjx.2016190037. doi: 10.13422/j.cnki.syfjx.2016190037
[8]	奚峰, 赵芳芳, 朱萍. 人参五味子汤对肺炎支原体肺炎肺脾气虚证患儿免疫功能及细胞因子水平的影响[J]. 新中医, 2019, 51(12):67-9.DOI: 10.13457/j.cnki.jncm.2019.12.020. doi: 10.13457/j.cnki.jncm.2019.12.020
[9]	韩征利, 董翠香, 曲政海, 等. 小青龙汤和人参五味子汤二步序贯治疗对哮喘小鼠呼吸道炎症与重塑的影响[J]. 实用儿科临床杂志, 2011(4):289-292.
[10]	陈皖晴, 曹亚娟, 吴建春, 等. 基于网络药理学预测“人参-五味子”药对治疗肺癌的作用机制[J]. 中华中医药学刊, 2020, 38(10):177-182.DOI: 10.13193/j.issn.1673-7717.2020.10.042 doi: 10.13193/j.issn.1673-7717.2020.10.042
[11]	RITCHIE M E, PHIPSON B, WU D, et al. Limma Powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Research, 2015, 43(7):e47. DOI: 10.1093/nar/gkv007. doi: 10.1093/nar/gkv007
[12]	RU J L, LI P, WANG J N, et al. TCMSP: a database of systems pharmacology for drug discovery from herbalmedicines[J]. Journal of Cheminformatics, 2014, 6:13. DOI: 10.1186/1758-2946-6-13. doi: 10.1186/1758-2946-6-13
[13]	XU X, ZHANG W X, HUANG C, et al. A novelchemometric method for the prediction of human oral bioavailability[J]. International Journal of Molecular Sciences, 2012, 13(6):6964-6982. DOI: 10.3390/ijms13066964. doi: 10.3390/ijms13066964
[14]	CONSORTIUM U. UniProt: a worldwide hub of protein knowledge[J]. Nucleic Acids Research, 2019, 47(D1):D506-D515. DOI: 10.1093/nar/gky1049. doi: 10.1093/nar/gky1049
[15]	GROSDIDIER A, ZOETE V, MICHIELIN O. Fast docking using the CHARMM force field with EADock DSS[J]. Journal of Computational Chemistry, 2011, 32(10):2149-2159. DOI: 10.1002/jcc.21797. doi: 10.1002/jcc.21797
[16]	BERMAN H M, WESTBROOK J, FENG Z, et al. The protein data bank[J]. Nucleic Acids Research, 2000, 28(1):235-242. DOI: 10.1093/nar/28.1.235. doi: 10.1093/nar/28.1.235
[17]	WANG Y L, BRYANT S H, CHENG T J, et al. PubChem BioAssay: 2017 update[J]. Nucleic Acids Research, 2017, 45(D1):D955-D963. DOI: 10.1093/nar/gkw1118. doi: 10.1093/nar/gkw1118
[18]	GROSDIDIER A, ZOETE V, MICHIELIN O. SwissDock, a protein-small molecule docking web service based on EADock DSS[J]. Nucleic Acids Research, 2011, 39:W270-W277. DOI: 10.1093/nar/gkr366. doi: 10.1093/nar/gkr366
[19]	CONSORTIUM T G O. Expansion of the Gene Ontology knowledgebase and resources[J]. Nucleic Acids Research, 2017, 45(D1):D331-D338. DOI: 10.1093/nar/gkw1108. doi: 10.1093/nar/gkw1108
[20]	DU J L, YUAN Z F, MA Z W, et al. KEGG-PATH: Kyoto encyclopedia of genes and genomes-based pathway analysis using a path analysis model[J]. Molecular bioSystems, 2014, 10(9):2441-2447. DOI: 10.1039/c4mb00287c. doi: 10.1039/c4mb00287c
[21]	陈玉宝, 俸珊, 曾杰, 等. 中国药典成方制剂中有关五味子配伍规律[J]. 中国药理学通报, 2017, 33(12):1771-1776.
[22]	HARASSTANI O A, THAM C L, ISRAF D A. Kaempferol and Chrysin Synergies to Improve Septic Mice Survival[J]. Molecules, 2017, 22(1):92. DOI: 10.3390/molecules22010092. doi: 10.3390/molecules22010092
[23]	IMAN V, MOHAN S, ABDELWAHAB S I, et al. Anticancer and anti-inflammatory activities of girinimbine isolated from Murraya koenigii[J]. Drug Design, Development and Therapy, 2017, 11:103-121. DOI: 10.2147/DDDT.S115135. doi: 10.2147/DDDT.S115135
[24]	ECKELBARGER J D, WILMOT J T, EPPERSON M T, et al. Synjournal of antiproliferative Cephalotaxus esters and their evaluation against several human hematopoietic and solid tumor cell lines: uncovering differential susceptibilities to multidrug resistance[J]. Chemistry, 2008, 14(14):4293-306. DOI: 10.1002/chem.200701998. doi: 10.1002/chem.200701998
[25]	QIAN Y, HUANG R R, LI S L, et al. Ginsenoside Rh2 reverses cyclophosphamide-induced immune deficiency by regulating fatty acid metabolism[J]. Journal of Leukocyte Biology, 2019, 106(5):1089-1100. DOI: 10.1002/JLB.2A0419-117R. doi: 10.1002/JLB.2A0419-117R
[26]	PASINI A, BRAND O J, JENKINS G, et al. Suberanilohydroxamic acid prevents TGF-β1-induced COX-2 repression in human lung fibroblasts post-transcriptionally by TIA-1 downregulation[J]. Biochimica et Biophysica Acta Gene Regulatory Mechanisms, 2018, 1861(5):463-472. DOI: 10.1016/j.bbagrm.2018.03.007. doi: 10.1016/j.bbagrm.2018.03.007
[27]	CHAKRABORTY K, CHATTERJEE S, BHATTACHARYYA A. Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis[J]. Tissue & Cell, 2018, 53:87-92. DOI: 10.1016/j.tice.2018.06.003. doi: 10.1016/j.tice.2018.06.003
[28]	MILAM J E, KESHAMOUNI V G, PHAN S H, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis[J]. American Journal of Physiology Lung Cellular and Molecular Physiology, 2008, 294(5):L891-L901. DOI: 10.1152/ajplung.00333.2007. doi: 10.1152/ajplung.00333.2007
[29]	刘豹, 忽新刚, 赵丽敏, 等. 麦门冬汤通过PPARγ抑制特发性肺间质纤维化中细胞氧化损伤的研究[J]. 中华中医药杂志, 2019, 34(11):5136-5140.
[30]	BALESTRO E, CALABRESE F, TURATO G, et al. Immune inflammation and disease progression in idiopathic pulmonary fibrosis[J]. PLoS One, 2016, 11(5):e0154516. DOI: 10.1371/journal.pone.0154516. doi: 10.1371/journal.pone.0154516
[31]	蔡杰, 谭利平, 冯佳, 等. 益气养阴方对肺间质纤维化大鼠肺组织TNF-α、TGF-β和IFN-γmRNA水平的影响[J]. 细胞与分子免疫学杂志, 2015, 31(7):894-897. DOI: 10.13423/j.cnki.cjcmi.007382. doi: 10.13423/j.cnki.cjcmi.007382

Metrics

Comments

Recommended 0

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits third parties to freely share (i.e., copy and redistribute the material in any medium or format) and adapt (i.e., remix, transform, or build upon the material) the articles published in this journal, provided that appropriate credit is given, a link to the license is provided, and any changes made are indicated. The material may not be used for commercial purposes. For details of the CC BY-NC 4.0 license, please visit: https://creativecommons.org/licenses/by-nc/4.0

序号	成分代码	成分名称	OB/%	DL	来源
1	MOL002879	己二酸二异辛酯	43.59	0.39	人参
2	MOL000449	豆甾醇	43.83	0.76	人参
3	MOL000358	β-谷甾醇	36.91	0.75	人参
4	MOL003648	高丽槐素	65.83	0.54	人参
5	MOL000422	山柰酚	41.88	0.24	人参
6	MOL005308	阿朴天仙子碱	66.65	0.22	人参
7	MOL005318	石竹胺	40.45	0.2	人参
8	MOL005320	花生四烯酸	45.57	0.2	人参
9	MOL005321	佛丁酮A	65.9	0.34	人参
10	MOL005344	人参皂苷rh2	36.32	0.56	人参
11	MOL005348	人参皂苷-Rh4苷元	31.11	0.78	人参
12	MOL005356	吉九里香碱	61.22	0.31	人参
13	MOL005376	人参萜二醇	33.09	0.79	人参
14	MOL005384	苏卡内酯	57.52	0.56	人参
15	MOL005399	胡萝卜甙	36.91	0.75	人参
16	MOL000787	蓝堇碱	59.26	0.83	人参
17	MOL005317	脱氧三尖杉酯碱	39.27	0.81	共同
18	MOL008957	五味子素B	30.71	0.83	五味子
19	MOL008968	五味子醇A	30.69	0.78	五味子
20	MOL008978	五味子醇R	34.84	0.86	五味子
21	MOL008992	五味子素C	46.27	0.84	五味子
22	MOL009213	五味子木脂素B	30.63	0.84	五味子
23	MOL009220	新南五味子素	33.35	0.88	五味子

序号	通路编号	通路名称	富集基因数	P值	富集基因
1	hsa04657	白介素17信号通路	8	2.22×10^-9	JUN, CASP8, MMP1, IFNG, CASP3, PTGS2, IL1B, MAPK8
2	hsa04668	肿瘤坏死因子信号通路	8	4.62×10^-9	ICAM1, JUN, CASP8, AKT1, CASP3, PTGS2, IL1B, MAPK8
3	hsa05418	流体剪切应力和动脉粥样硬化	7	7.40×10^-8	ICAM1, JUN, CASP8, AKT1, CASP3, PTGS2, IL1B
4	hsa04933	糖尿病并发症AGE-RAGE信号通路	6	1.63×10^-6	ICAM1, JUN, AKT1, CASP3, IL1B, MAPK8
5	hsa04625	C型凝集素受体信号通路	6	1.66×10^-6	JUN, CASP8, AKT1, PTGS2, IL1B, MAPK8
6	hsa05152	肺结核	6	1.66×10^-6	CASP8, AKT1, NOS2, IFNG, CASP3, IL1B
7	hsa04380	破骨细胞分化	6	3.55×10^-6	JUN, AKT1, IFNG, IL1B, MAPK8, PPARG
8	hsa05145	麻疹	6	5.04×10^-6	CASP8, AKT1, NOS2, IFNG, CASP3, MAPK8
9	hsa05133	百日咳	5	5.71×10^-6	JUN, NOS2, CASP3, IL1B, MAPK8
10	hsa05164	甲型流感	6	1.19×10^-5	ICAM1, CASP8, AKT1, IFNG, CASP3, IL1B

序号	关键靶点	活性成分	对接能量ΔG/(kJ·mol^-1)
1	AKT1	山奈酚(Kaempferol)	-30.14
2		豆甾醇(Stigmasterol)	-33.86
3		β-谷甾醇(Beta-sitosterol)	-36.21
4		高丽槐素(Inermin)	-32.98
5		山奈酚(Kaempferol)	-30.43
6		石竹胺(Dianthramine)	-30.39
7	PTGS2	花生四烯酸(Arachidonate)	-34.07
8		佛丁酮A (Frutinone A)	-29.30
9		人参皂苷rh2(Ginsenoside rh2)	-39.77
10		吉九里香碱(Girinimbin)	-32.78
11		苏卡内酯(Suchilactone)	-34.58
12		蓝堇碱(Fumarine)	-30.05
13		五味子素B (Schizandrer B)	-36.46
14	IL1B	人参皂苷rh2(Ginsenoside rh2)	-29.01
15	MAPK8	山奈酚(Kaempferol)	-31.23
16		β-谷甾醇(Beta-sitosterol)	-28.17
17	CASP3	山奈酚(Kaempferol)	-26.96
18		人参皂苷rh2(Ginsenoside rh2)	-29.43

Molecular mechanism of Ginseng Radix Et Rhizoma-Schisandrae Chinensis Fructus couple medicine in the treatment of idiopathic pulmonary fibrosis based on network pharmacology and molecular docking

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 31

Related Articles 15

Metrics

Comments

Recommended 0

[1]	MIAO Ran, GUAN Yongxia, GUO Huanying, ZHANG Guimin, WANG Xiao, ZHAO Hengqiang. Quality control study of Jingfang granules through combined fingerprinting and comprehensive assessment of activity [J]. Shandong Science, 2025, 38(5): 22-30.
[2]	GUO Yingjian, YU Jinqian, DONG Hongjing, WANG Chuangchuang, ZHONG Kai, WANG Xiao. Topological analysis reveals mechanism of Panax notoginseng saponin in the treatment of gouty arthritis based on network pharmacology and in vitro experiments [J]. Shandong Science, 2025, 38(5): 40-48.
[3]	SUN Jingtian, LIU Feng, ZHANG Zhe, ZHANG Yufu, MA Xinhui, LI Qingjun, WANG Xiao, DONG Hongjing. Exploring the medication rule of Chrysanthemum morifolium Ramat. and investigating the synergistic pharmacological activity of core combination herbs [J]. Shandong Science, 2025, 38(1): 1-8.
[4]	HAN Huijie, LIU Hui, ZHAO Yongbo, WANG Songpo. A study based on network pharmacology and experimental verification exploring the mechanism of quercetin against colorectal cancer through the p53 signaling pathway [J]. Shandong Science, 2025, 38(1): 32-43.
[5]	FAN Wei, SHEN Chuanlin, ZHANG Xuanming, DU Xingshuo, ZHAN Wen, SUN Chen, JIN Meng, LI Xiaobin, ZHANG Sichen, SUN Botong, HE Qiuxia. Prediction of anti-aging mechanism of Panax quinquefolius L. by network pharmacology and molecular docking [J]. Shandong Science, 2024, 37(6): 42-50.
[6]	YAN Jin, LI Fei, WU Keming, YANG Haobo. The molecular mechanisms by which Xinjia Cistanche Tusi Decoction promotes follicular development through mitophagy [J]. Shandong Science, 2024, 37(5): 25-34.
[7]	LIN Shenghua, XUE Chang, MA honglin, FAN Wei, SHEN Chuanlin, CHEN Jiayu, SUN Botong, DU Xingshuo, ZHAN Wen, LI Xiaobin, ZHANG Shanshan, JIN Meng, HE Qiuxia. Study of the active components and mechanism of action of antithrombotic Xuefuzhuyu oral liquid based on network pharmacology and molecular docking technology [J]. Shandong Science, 2024, 37(4): 26-33.
[8]	MA Shijing, HE Chunyan, GUAN Tianzhu, YAO Xueshuang, ZHANG Junpeng. Exploration of antihyperlipidemia mechanism of Monopterus albus peptides based on hyperlipidemic zebrafish model and network pharmacology [J]. Shandong Science, 2024, 37(3): 27-38.
[9]	WEI Zekun, YANG Yujie, LIU Shuang, WANG Yan, DONG Hongjing, LIU Chunmei. Reverse mining of Chinese medicine for intervention of liver cancer based on GEO database combined with network pharmacology and molecular docking technology [J]. Shandong Science, 2024, 37(3): 39-47.
[10]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[11]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[12]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[13]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[14]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[15]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.